文献速递胸部肿瘤

免疫细胞浸润可能是小细胞肺癌长期生存的关键决定因素

Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2019-05-09

本研究对比了23例生存超过4年的小细胞肺癌长期生存者与18例生存不超过2年的预期生存者的手术切除肿瘤,发现长期生存者中免疫相关基因和通路多数呈差异性高表达,肿瘤浸润淋巴细胞增多,抑制性免疫细胞与CD3阳性淋巴细胞比值普遍较低,提示抗肿瘤免疫微环境与长期生存相关。

要点

  • 长期生存者肿瘤中免疫相关基因和通路多数呈差异性高表达。
  • 长期生存者肿瘤内浸润及相关淋巴细胞数量增多。
  • 长期生存者肿瘤中抑制性免疫细胞与CD3阳性淋巴细胞比值普遍较低。

核心结论

  • 小细胞肺癌患者的长期生存受肿瘤微环境中免疫细胞存在的强烈影响。
  • 表征抗肿瘤免疫反应可能为小细胞肺癌的个体化免疫治疗提供机会。

研究设计与样本

  • 比较23例长期生存(生存>4年)与18例预期生存(生存≤2年)小细胞肺癌患者手术切除肿瘤的基因组和肿瘤微环境分析。
  • 两组间临床变量包括TNM分期和治愈性与非治愈性手术意图无显著差异。
  • 基因表达谱采用微阵列分析,肿瘤微环境分析采用免疫组化检测主要免疫相关标志物。

主要发现

  • 与预期生存者相比,长期生存者中免疫相关基因和通路占差异性高表达基因的大多数。
  • 定量免疫染色证实了免疫肿瘤微环境的差异。
  • 长期生存者肿瘤全区域存在增多的肿瘤浸润及相关淋巴细胞。
  • 鉴定出几种增强抗肿瘤免疫的分化模式。
  • 长期生存者肿瘤部分区域也含有较高数量的抑制性免疫细胞(单核细胞、调节性淋巴细胞和巨噬细胞),但这些抑制细胞与CD3阳性淋巴细胞的比值在长期生存者肿瘤中普遍较低,表明肿瘤抑制性微环境较弱。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although most patients with SCLC die within a few months of diagnosis, a subgroup of patients survive for many years. Factors determining long-term survivorship remain largely unknown. We present the first comprehensive comparative genomic and tumor microenvironment analyses of SCLC between patients with long-term survivorship and patients with the expected survivorship. METHODS: We compared surgically resected tumors of 23 long-term SCLC survivors (survival >4 years) and 18 SCLC survivors with the expected survival time (survival ≤2 years). There were no significant differences in clinical variables, including TNM staging and curative- versus non-curative-intent surgery between the groups. Gene expression profiling was performed by using microarrays, and tumor microenvironment analyses were performed by immunohistochemistry of prominent immune-related markers. RESULTS: Immune-related genes and pathways represented the majority of the differentially overexpressed genes in long-term survivorship compared with in expected survivorship. The differences in the immunological tumor microenvironment were confirmed by quantitative immunostaining. Increased numbers of tumor-infiltrating and associated lymphocytes were present throughout tumors of long-term survivors of SCLC. Several differentiating patterns of enhanced antitumor immunity were identified. Although some areas of the tumors of long-term survivors of SCLC also harbored higher numbers of suppressive immune cells (monocytes, regulatory lymphocytes, and macrophages), the ratios of these suppressive cells to CD3-positive lymphocytes were generally lower in the tumors of long-term survivors of SCLC, indicating a less tumor-suppressive microenvironment. CONCLUSIONS: Our data demonstrate that long-term survivorship of patients with SCLC is strongly influenced by the presence of the immune cells in the tumor microenvironment. Characterization of the antitumor immune responses may identify opportunities for individualized immunotherapies for SCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Muppa P, Parrilha Terra SBS, Sharma A, et al. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer. J Thorac Oncol. 2019. PMID: 31078775. doi:10.1016/j.jtho.2019.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。